News

The Government of New Brunswick added  Lemtrada (alemtuzumab), by Sanofi Genzyme, to the New Brunswick Prescription Drug Program (NBPDP) through special authorization for eligible patients with relapsing-remitting multiple sclerosis (RRMS). New Brunswick joins other Canadian provinces, including Ontario, Saskatchewan, Quebec, and Manitoba, in making this treatment available to RRMS patients, ages 18 and older, who have had…

Patients with secondary progressive multiple sclerosis (SPMS) who were treated with BAF312 (siponimod), a sphingosine-1-phosphate (S1P) inhibitor, in a Phase 3 clinical trial showed a  significantly reduced risk for disability progression compared to placebo, Novartis recently announced. BAF312 is a selective modulator of specific types of the S1P receptor. This receptor is…

The Quebec Division of the Multiple Sclerosis Society of Canada (MSSC)  announced that this year’s 27th Medavie Blue Cross MS Bike, a fundraising bike ride on roads alongside St. Lawrence River, will take place Aug. 27 and 28 in the Mauricie region. A total of 900 cyclists are set to participate in…

The National Multiple Sclerosis Society  announced that it has dedicated more than $1 million to support a clinical study at the University of Iowa that will compare two types of diet and their effectiveness in easing fatigue in people with multiple sclerosis (MS). “The National MS Society is committed to identifying wellness solutions to…

Health Canada has approved Teva Canada Innovation‘s three-time weekly 40 mg/mL injection of Copaxone (glatiramer acetate) that allows less frequent dosing for patients with relapsing-remitting multiple sclerosis (RRMS). The approval was grounded primarily on data resulting from the Phase 3 Glatiramer Acetate Low-Frequency Administration (GALA) study, the largest Copaxone clinical…

An innovation in multiple sclerosis (MS) research has been launched by the iConquerMS initiative — a longitudinal, prospective study called “REAL MS,” an acronym for “Research Engagement About Life with Multiple Sclerosis,” with a goal of accelerating research into personalized treatments for MS patients. This type of study collects repeat…

Multiple sclerosis seems to be less severe in people with higher levels of the minor adult hemoglobin variant A2 (HbA2) in their blood, according to a team of Turkish researchers. This could be due to this variant having a higher protective effect on the red blood cell membrane. The authors speculate that HbA2 could therefore be playing a role in reducing long-term neural injury in MS.

People with relapsing multiple sclerosis who use a device called RebiSmart (Merck Serono) to self-inject medications like Rebif (interferon [IFN] beta-1a) are more likely to take their therapies on a regular schedule and adhere to that schedule, resulting in fewer relapses than those not using the device, according to a retrospective study by  researchers…

In the two years following my diagnosis, I had many bouts of chest pain, breathing difficulties, and sharp stomach pains. I worried that some other terrible illness was right around the corner. Four EKGs, three ultrasounds, two pulmonary function tests, and one colonoscopy later I had a surprisingly good bill…

A new video series for multiple sclerosis patients in the U.S. looks to help them better understand the complex legal and planning issues they face. The series, put together by the National Academy of Elder Law Attorneys (NAELA) and Stetson University College of Law, in consultation with the National Multiple Sclerosis Society, is…

General practitioners (GPs) in England lack confidence in initially assessing and referring onward people with neurological symptoms, especially those with multiple sclerosis, and believe they could benefit from better training in identifying and managing neurological patients. One result, according to a report published by the Neurological Alliance, titled “Neurology and primary care: improving the…

Here’s my Pick of the Week’s News, as published in Multiple Sclerosis News Today. Blood Test Seen to Distinguish MS from Other Neurological Conditions A faster way to tell the difference between neurological diseases could mean earlier access to treatment for MS patients. Researchers at Michigan State…

A&W Food Services of Canada is celebrating its “Burgers to Beat MS” day on Thursday, Aug. 25, and for an 8th year will donate $1 for each Teen Burger sold at any of its 860 restaurants nationwide to the Multiple Sclerosis Society of Canada (MSSC). Through such campaigns, A&W has  raised over $8 million since 2009…

A cell therapy product derived from human umbilical cord blood cells may be a promising treatment approach for patients with demyelinating diseases, such as multiple sclerosis (MS) or leukodystrophy, according to a recent study developed at the Duke University Medical Center. The study, “A cord blood monocyte–derived cell…

Researchers at Michigan State University suggest that a blood test can distinguish patients with multiple sclerosis (MS) from people with other neurological conditions, according to a recent study published in EBioMedicine. Results from the study, “An In Vitro Diagnostic for Multiple Sclerosis Based on C-peptide Binding to Erythrocytes,”…

Relapsing multiple sclerosis patients who begin taking Betaferon/Betaseron (interferon beta-1b) immediately after the first MS-related neurologic symptoms appear may realize slower disease progression than those who delay treatment, according to a study evaluating the therapy’s effects over a decade in patients enrolled in a Phase 3 clinical trial. The study, “The 11-year long-term follow-up…

There are several key questions that a participant will want answered before enrolling in a clinical trial. Many are listed here, but patients should feel free to ask study coordinators any additional questions they may have so their concerns are well addressed before the trial starts. It is important for a study participant to learn as…

Researchers from Colorado State University propose a new model of fatigue in multiple sclerosis (MS), designed to overcome the lack of a unified definition of fatigue that can be objectively tested using experimental approaches. With this model, the authors behind the article, “Fatigue in Multiple Sclerosis: Misconceptions…

The 37th annual congress of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will take place in London between 14 – 17 September 2016.

According to new research out of McGill University in Montreal, Microsoft Kinect, a 3-D depth and motion sensing input device for use with the company’s Xbox 360 and Xbox One video game consoles and Windows PCs, could be a cheap, effective, and easy-to-use tool to evaluate walking gait difficulties in people with multiple…

Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., is now dispensing the limited-distribution drug Zinbryta (daclizumab) as a therapy for relapsing multiple sclerosis (MS). Zinbryta was recently approved by the U.S. Food and Drug Administration (FDA), and is indicated for the treatment of adult patients with relapsing MS.

Earth Life Sciences (ELS), a venture capital and management firm based in Quebec, announced that it is partnering with a cannabis oil-based nutraceutical company, with an agreement in place to acquire that company and establish a new division. The resulting entity will be an organic medical marijuana oils (CBD) producer that will develop products…

The Multiple Sclerosis Association of America (MSAA) recently announced the official launch of My MSAA Community, a free online community forum supporting people with multiple sclerosis (MS), and their caregivers and family members, and offering a way for patients to connect with others facing the same challenges. MSAA is…

Here’s my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Best First-Line Treatment for Aggressive MS May Be Equally Aggressive Immunotherapies Sounds like “Fight fire with fire” to me; could be just what is needed. Patients with aggressive onset multiple sclerosis, characterized…

Scientists at Stanford University School of Medicine have developed a method for stem cell transplants that may do away with the need for prior systematic treatment with chemotherapy or radiotherapy. If successful, stem cell transplants could be an option for patients with multiple sclerosis (MS), an option now limited by the…

A long-term study underscores the potential benefits, especially in terms of relapses, of multiple sclerosis (MS) patients beginning treatment as soon as possible after symptoms appear — even before the disease is definitely diagnosed. “The 11-year long-term follow-up study from the randomized BENEFIT CIS trial” was published in the journal Neurology. Researchers in…

Researchers found the molecular target of the multiple sclerosis (MS)-approved drug Tecfidera, (dimethyl fumarate or DMF), unveiling the mechanism associated with the drug’s anti-inflammatory action. The study, “Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation,” was…

Though approved therapies for multiple sclerosis (MS) exist, the disabling disease remains currently incurable leading to greater interest for promoting healthier lifestyles that could ease or slow disease impacts such as hyperlipidemia, hypertension, diabetes, and heart disease which increase progression of disability, brain injury, and atrophy. In fact,…

Increasing a person’s confidence that they can complete tasks and reach goals in specific situations may benefit patients with relapsing-remitting multiple sclerosis (RRMS). In a new study, researchers used an intensive three-day social cognitive treatment, called Can Do, to increase patients’ self-efficacy, which resulted in long lasting improvements in their health-related…

A large study of multiple sclerosis patients (MS) came to the conclusion that clinical and brain imaging assessments drawn from magnetic resonance imaging (MRI) scans are poor measures of long-term prognosis for patients. The study, “Long-term evolution of multiple sclerosis disability in the treatment era,” published in the journal…